Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million financing
Lucid Diligence Brief: Tortugas Neuroscience launches with $106 million…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…
Lucid Diligence Brief: Stipple Bio $100 million Series A
Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B
Lucid Diligence Brief: Pinnacle Medicines $89 million Series B Professional…
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets
Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration
Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal
Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…

